Did you miss the live broadcast? Stay engaged in recent updates and key findings in NSCLC immuno-oncology with this webcast from our virtual grand rounds series.
1.0 AMA PRA Category 1 Credits™
Dec 6, 2018
Dec 6, 2019
News in Lung Immunotherapy: Updates from Recent Meetings
Enriqueta Felip, MD, PhD
Enriqueta Felip, MD, PhDVall d’Hebron University Hospital
This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer, melanoma, or bladder cancer.
After successful completion of this educational activity, participants should be able to:
- Examine the evidence for the role of biomarkers in immuno-oncology and how to apply them in clinical practice
- Select optimal immunotherapy approach for patients with cancer
- Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents
- Develop strategies to recognize and manage adverse events resulting from the use of immunotherapies
Best Practices in Melanoma Immunotherapy
Dirk Schadendorf, MD
A Practical Application of Data in Bladder Cancer Immunotherapy
Ronald de Wit, MD, PhD
Immunotherapy in Lung Cancer: The News From Major Lung Conferences in 2018
Benjamin Besse, MD, PhD
Decision-Making in NSCLC Immunotherapy
Solange Peters, MD, PhD
Challenging Cases in Melanoma Immunotherapy
Caroline Robert, MD
This educational activity is supported by a grant from Merck Sharp and Dohme Corp.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Disclosure of Relevant Financial Relationships
prIME Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to prIME Oncology policy. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Felip has disclosed board membership, consulting fees, and honoraria for promotional speaker’s bureaus from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Merck, Merck Sharpe and Dohme, Novartis, Pfizer, Roche, and Takeda. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed no relevant financial relationships.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.